171 related articles for article (PubMed ID: 12199781)
1. Abnormal WT1 expression in the CD34-negative compartment in myelodysplastic bone marrow.
Van Dijk JP; Knops GH; Van De Locht LT; Menke AL; Jansen JH; Mensink EJ; Raymakers RA; De Witte T
Br J Haematol; 2002 Sep; 118(4):1027-33. PubMed ID: 12199781
[TBL] [Abstract][Full Text] [Related]
2. WT1 gene expression: useful marker for minimal residual disease in childhood myelodysplastic syndromes and juvenile myelo-monocytic leukemia?
Bader P; Niemeyer C; Weber G; Coliva T; Rossi V; Kreyenberg H; Gerecke A; Biondi A
Eur J Haematol; 2004 Jul; 73(1):25-8. PubMed ID: 15182334
[TBL] [Abstract][Full Text] [Related]
3. [Expression of WT1 and PRAME gene in bone marrow and peripheral blood samples of patients with myelodysplastic syndrome].
Lu D; Qin YZ; Li LD; Shi HX; Lai YY; Liu YR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):370-6. PubMed ID: 24763007
[TBL] [Abstract][Full Text] [Related]
4. Apparent expansion of CD34+ cells during the evolution of myelodysplastic syndromes to acute myeloid leukemia.
Span LF; Dar SE; Shetty V; Mundle SD; Broady-Robinson L; Alvi S; Raymakers RA; de Witte T; Raza A
Leukemia; 1998 Nov; 12(11):1685-95. PubMed ID: 9823942
[TBL] [Abstract][Full Text] [Related]
5. Differential gene expression of bone marrow CD34+ cells in early and advanced myelodysplastic syndrome.
Vasikova A; Budinska E; Belickova M; Cermak J; Bruchova H
Neoplasma; 2009; 56(4):335-42. PubMed ID: 19469654
[TBL] [Abstract][Full Text] [Related]
6. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes.
Cilloni D; Gottardi E; Messa F; Fava M; Scaravaglio P; Bertini M; Girotto M; Marinone C; Ferrero D; Gallamini A; Levis A; Saglio G;
J Clin Oncol; 2003 May; 21(10):1988-95. PubMed ID: 12743153
[TBL] [Abstract][Full Text] [Related]
7. [Expression of Fas, FasL and Bcl-2 and apoptosis of bone marrow CD34+ cells in patients with myelodysplastic syndrome].
Zhang Z; Xie J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Jun; 11(3):274-7. PubMed ID: 12844412
[TBL] [Abstract][Full Text] [Related]
8. T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy.
Sloand EM; Melenhorst JJ; Tucker ZC; Pfannes L; Brenchley JM; Yong A; Visconte V; Wu C; Gostick E; Scheinberg P; Olnes MJ; Douek DC; Price DA; Barrett AJ; Young NS
Blood; 2011 Mar; 117(9):2691-9. PubMed ID: 21097671
[TBL] [Abstract][Full Text] [Related]
9. Associations between the peripheral blood Wilms tumor gene 1 level and both bone marrow blast cells and the prognosis in patients with myelodysplastic syndrome.
Mashima K; Ikeda T; Toda Y; Ito S; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Yamamoto C; Fujiwara S; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Leuk Lymphoma; 2019 Mar; 60(3):703-710. PubMed ID: 30188227
[TBL] [Abstract][Full Text] [Related]
10. [Differentiation and expression of membrane hemopoietic cytokine receptors on CD34+ bone marrow cells in patients with myelodysplastic syndromes].
Li LJ; Fu R; Wang HQ; Yue LZ; Liu H; Wang J; Wang HL; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Song J; Wu YH; Xing LM; Guan J; Shao ZH
Zhonghua Yi Xue Za Zhi; 2011 Jan; 91(4):234-8. PubMed ID: 21418866
[TBL] [Abstract][Full Text] [Related]
11. Wilms Tumor 1 (WT1) mRNA Expression Level at Diagnosis Is a Significant Prognostic Marker in Elderly Patients with Myelodysplastic Syndrome.
Nagasaki J; Aoyama Y; Hino M; Ido K; Ichihara H; Manabe M; Ohta T; Mugitani A
Acta Haematol; 2017; 137(1):32-39. PubMed ID: 27866185
[TBL] [Abstract][Full Text] [Related]
12. Very low frequencies of human normal CD34+ haematopoietic progenitor cells express the Wilms' tumour gene WT1 at levels similar to those in leukaemia cells.
Hosen N; Sonoda Y; Oji Y; Kimura T; Minamiguchi H; Tamaki H; Kawakami M; Asada M; Kanato K; Motomura M; Murakami M; Fujioka T; Masuda T; Kim EH; Tsuboi A; Oka Y; Soma T; Ogawa H; Sugiyama H
Br J Haematol; 2002 Feb; 116(2):409-20. PubMed ID: 11841446
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of WT1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes.
Ueda Y; Mizutani C; Nannya Y; Kurokawa M; Kobayashi S; Takeuchi J; Tamura H; Ogata K; Dan K; Shibayama H; Kanakura Y; Niimi K; Sasaki K; Watanabe M; Emi N; Teramura M; Motoji T; Kida M; Usuki K; Takada S; Sakura T; Ito Y; Ohyashiki K; Ogawa H; Suzuki T; Ozawa K; Imai K; Kasai M; Hata T; Miyazaki Y; Morita Y; Kanamaru A; Matsuda A; Tohyama K; Koga D; Tamaki H; Mitani K; Naoe T; Sugiyama H; Takaku F
Leuk Lymphoma; 2013 Jul; 54(7):1450-8. PubMed ID: 23110324
[TBL] [Abstract][Full Text] [Related]
14. [Clinical significance of the Wilms' tumor 1 mRNA expression in childhood myelodysplastic syndrome].
Cheng YF; Zhang LP; Liu YR; Qin YZ; Wu J; Liu GL
Zhonghua Xue Ye Xue Za Zhi; 2012 Jul; 33(7):536-40. PubMed ID: 22967413
[TBL] [Abstract][Full Text] [Related]
15. DNA methylation profiling of myelodysplastic syndrome hematopoietic progenitor cells during in vitro lineage-specific differentiation.
Hopfer O; Komor M; Koehler IS; Schulze M; Hoelzer D; Thiel E; Hofmann WK
Exp Hematol; 2007 May; 35(5):712-23. PubMed ID: 17577921
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of TET2 in CD3⁺ and CD34⁺ cells of myelodysplastic syndromes and enhances CD34⁺ cells proliferation.
Zhang W; Shao Z; Fu R; Wang H; Li L; Liu H
Int J Clin Exp Pathol; 2015; 8(9):10840-6. PubMed ID: 26617797
[TBL] [Abstract][Full Text] [Related]
17. WT1 Expression in Patients with Myelodysplastic Syndromes: A Variety of Possibilities in Future Clinical Practice.
Ogata K
Acta Haematol; 2017; 137(1):30-31. PubMed ID: 27871071
[No Abstract] [Full Text] [Related]
18. GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34(+) and erythroid CD71(+) cells in myelodysplastic syndromes.
Maratheftis CI; Bolaraki PE; Voulgarelis M
Am J Hematol; 2007 Oct; 82(10):887-92. PubMed ID: 17570514
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of the Doppel protein in acute myeloid leukaemias and myelodysplastic syndromes.
Travaglino E; Comincini S; Benatti C; Azzalin A; Nano R; Rosti V; Ferretti L; Invernizzi R
Br J Haematol; 2005 Mar; 128(6):877-84. PubMed ID: 15755294
[TBL] [Abstract][Full Text] [Related]
20. PRAME and WT1 transcripts constitute a good molecular marker combination for monitoring minimal residual disease in myelodysplastic syndromes.
Qin YZ; Zhu HH; Liu YR; Wang YZ; Shi HX; Lai YY; Xu LP; Liu DH; Jiang Q; Li LD; Jiang B; Liu KY; Huang XJ
Leuk Lymphoma; 2013 Jul; 54(7):1442-9. PubMed ID: 23110703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
